HeartFlow said today it won positive medical policy decisions from 4 different Blue Cross Blue Shield groups across the US for its HeartFlow FFRct fractional flow reserve technology.
The Redwood City, Calif.-based company said that Horizon BCBS of New Jersey, BCBS of Arizona, BCBS of Idaho and BCBS of Kansas City issued determinations supporting the use of the company’s noninvasive FFRct, following a positive coronary computed tomography angiogram, for patients with stable chest pain.
“These new coverage decisions add to the growing number of payers that have reviewed evidence from clinical trials demonstrating that the HeartFlow FFRct Analysis helps improve clinical outcomes, reduces unnecessary invasive diagnostic procedures, and reduces healthcare costs. These payers have made the decision to cover HeartFlow’s noninvasive technology because they recognize the benefit it can provide to patients with suspected CAD. Together with the American Medical Association’s decision to issue a set of Category III CPT codes for HeartFlow FFRct Analysis, we are seeing increasing acceptance and adoption of our non-invasive technology by clinicians and top medical centers throughout the United States and around the world. The HeartFlow FFRct Analysis is helping physicians determine which patients with suspected CAD have clinically significant disease and how they should be optimally treated,” CEO Dr. John Stevens said in a press release.
The 4 BCBS groups cover approximately 5.5 million individuals, HeartFlow said.
In early July, HeartFlow said it won a new set of category III Current Procedural Terminology codes from the American medical Association for its FFRct fractional flow reserve technology.
The CPT code application was submitted by the American College of Cardiology, the Society of Cardiovascular Computed Tomography and the Society for Cardiovascular Angiography and Interventions, the company said.